What’s inside
View ResearchDiscover the findings of the Pre-POInT-early study, a randomized trial investigating oral insulin immunotherapy in children at risk for type 1 diabetes. This trial assesses the safety and immune responses in genetically predisposed infants, showing that oral insulin is well-tolerated and modifies immune responses based on the INS genotype. The study also highlights interactions between oral insulin therapy, the gut microbiome, and immune responses during early childhood.
Oral Insulin Immunotherapy for Type 1 Diabetes
Study on oral insulin immunotherapy's safety and immune efficacy in preventing type 1 diabetes in genetically at-risk children.
Safety of Oral Insulin in Young Children
Oral insulin administration in children aged 6 months to 2 years shows no hypoglycemia or adverse metabolic effects.
Immune Response to Oral Insulin in Children
Analysis of antibody and T cell responses to oral insulin in children with genetic susceptibility to type 1 diabetes.
INS Gene and Immune Modulation by Oral Insulin
Study reveals INS genotype's role in modulating immune responses to oral insulin, influencing antibody production and microbiome.
Microbiome Changes with Oral Insulin Therapy
Oral insulin therapy associated with microbiome alterations, particularly in children with the susceptible INS AA genotype.
Inflammatory Episodes in Children on Oral Insulin
Frequent inflammatory episodes observed during oral insulin therapy, linked to type 1 interferon responses and immune activation.
.svg)
.jpg)
.webp)
